Royalty Report: Drugs, Pain, Pharmaceuticals – Collection: 3265

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Pain
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Addiction
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3265

License Grant
The Licensor will grant the Licensee a non-exclusive, royalty-bearing future license to the Licensor Patent and other current and future Orange Book listable patents to market, manufacture and sell a generic version of Oxecta® in the United States.

The Licensee's license becomes effective January 1, 2022, approximately 23 months prior to the expected expiration of the Licensor Patent.

License Property
OXECTA is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

In June 2011, the U.S. Food and Drug Administration approved Oxecta® (oxycodone HC1 tablets) which incorporates the Aversion® technology. Oxecta® is an abuse-deterrent opioid analgesic formulation.

Field of Use
The Field of Use apply to the healthcare industry.

IPSCIO Record ID: 3297

License Grant
This Agreement settles the parties patent infringement litigation concerning Licensor's AVERSION® oxycodone product, previously marketed by Pfizer Inc. under its brand name Oxecta® (oxycodone HCI tablets).

In the suit, Licensor alleges that a generic AVERSION® oxycodone product for which Licensee is seeking approval to market in the U.S. pursuant to an Abbreviated New Drug Application filing with the U.S. Food and Drug Administration infringes a U.S. patent owned by Licensor .

Under the terms of the Settlement Agreement, Licensor will grant Licensee a non-exclusive, royalty-bearing license to the Licensor Patent and other current and future Orange Book listable patents to market, manufacture and sell a generic version of AVERSION® oxycodone in the United States. Licensee's license becomes effective 180 days following the first sale of a generic AVERSION® oxycodone

product in the United States by an entity that is entitled to the 180 day first-filer exclusivity provided in the Drug Price Competition.

The Settlement Agreement will remain in effect until the expiration of the term of the license granted by tbe Licensor to the Licensee.

License Property
AVERSION® oxycodone is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

IPSCIO Record ID: 1310

License Grant
Oxecta will be manufactured and is being commercialized by Licensee under a license agreement.
License Property
Oxecta is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. This Aversion ® Technology is a unique composition of commonly used pharmaceutical ingredients.

IPSCIO Record ID: 1208

License Grant
Licensor grants an exclusive license under the Technology to Develop, manufacture, have manufactured, import, use and Commercialize Products in the Field in the Territory, including the right to conduct clinical Development of the Products outside the Territory in support of Development and Commercialization of such Products in the Territory, including the right to grant sublicenses.

Licensor grants an exclusive license under the Technology, including foreign counterparts and equivalents of patent rights to the extent any exist, to manufacture and have manufactured Products outside the Territory in order to import, use and Commercialize Products in the Field in the Territory, including the right to grant sublicenses.

Licensor grants an exclusive license to use the Trademarks to Commercialize, including to advertise, promote and distribute, the Products in the Field in the Territory.

Licensor grants an exclusive license to exploit the Domain Names in connection with the Products.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor has developed Aversion® Technology and related products intended to deter pharmaceutical product abuse.

Aversion® Composition means a composition having a gel forming polyethylene oxide, sodium lauryl sulfate, and crospovidone.

Product A means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 7.5mg with each tablet containing the Aversion® Composition with niacin at 30mg.

Product B means an immediate release pharmaceutical product for human use, intended for oral administration in two tablet strengths oxycodone HCl 5.0mg and 10.0mg with each tablet containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.

Product C means an immediate release Future Product in three tablet strengths hydrocodone bitartrate 5.0mg, 7.5mg, and 10.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg and acetaminophen 325mg.

Product D means an immediate release Future Product [in three tablet strengths hydromorphone HCl 2.0mg, 4.0mg, and 8.0mg with each tablet also containing the Aversion® Composition with niacin at 30mg.

Trademarks means Aversion®, Acurox™, and Acuracet™.

The patents are for Methods and Compositions for Deterring Abuse of Opioid.

Acurox®, Acuracet® (oxycodone HCI/niacin/APAP) Tablets, Vycavert® (hydrocodone bitartrate/niacin/APAP) Tablets and a fourth undisclosed opioid analgesic product candidate utilizing our proprietary Aversion® Technology.

The Licensee has an option to License in the  territory all future opioid analgesic products developed utilizing Aversion® Technology. The Agreement provides that Licensor or Licensee may develop additional opioid analgesic product candidates utilizing our Aversion® Technology and, if Licensee exercises its option to License such additional product candidates, they will be subject to the milestone and royalty payments and other terms of the Agreement.

The drug is part of a class of opioid analgesic products for treatment for moderate to severe acute pain.

The Licensor is responsible, using commercially reasonable efforts, for all Acurox® Tablet development activities through FDA approval of a 505(b)(2) NDA, for which our expenses are reimbursed to us by the Licensee. After NDA approval the Licensee will be responsible for manufacturing and commercializing Acurox® Tablets in the U.S.

Field of Use
The Field means all present and future indications, as a human therapeutic, for use of the Products for the treatment of pain.

IPSCIO Record ID: 253953

License Grant
The Parties have entered into a Settlement Agreement.  As a result of and pursuant to the Settlement Agreement,  the Licensor grants a limited, non-exclusive,  non-transferable license of limited duration under the Patent to make, have made, use, offer to Sell and Sell, in the United States, up to an aggregate of 800,000 bottles, subject to the reductions set forth below, of the generic versions of 10 mg, 15mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg dosage strengths of the Licensee Products, allocated among the dosage strengths.
License Property
The patent is relating to and protecting controlled-release oxycodone products, including the product OxyContin®, a controlled-release oxycodone product marketed and sold under NDA No. 20-553 OxyContin®.
Field of Use
Licensee is a specialty branded pharmaceutical company.  The product is for the management of pain with opioid analgesics.

IPSCIO Record ID: 369250

License Grant
Licensor grants, as of the date of execution of this Agreement, a personal, perpetual, exclusive and nontransferable right and license under the Product Intellectual Property, to make, have made, use, offer to sell, sell and import Products in the Field in the Territory for the sole purpose of completing the Pre-Launch Marketing Activities prior to the transfer of the NDA, and, thereafter a transferable license for the sole purpose of Commercialization of the Product in the Territory.
License Property
Licensor owns certain Intellectual Property Rights related to Intravenous Tramadol HCl, the Product, and is seeking approval from the FDA for the marketing and sale of products that incorporates or is comprised of Tramadol.

The Product shall mean Intravenous Tramadol HC1.

The patent is for Intravenous Administration of Tramadol.

Field of Use
Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain. It is available as immediate release or extended-release tablets.  Tramadol is used to treat moderate to severe pain in adults.

IPSCIO Record ID: 26587

License Grant
We have licensed exclusive, worldwide, development and commercialization rights under an Agreement.

Remoxy is formulated with our Oradur technology and incorporates several abuse-deterrent properties with the convenience of twice-a-day dosing. Oxycodone is also the active drug ingredient in OxyContin®, a brand name narcotic painkiller.  Remoxy is intended for patients with chronic pain. Remoxy is currently in Phase III trials.

Field of Use
The rights granted apply to the pain management industry.

IPSCIO Record ID: 262471

License Grant
The Company granted Licensee the right to commercialize the NUCYNTA franchise of pain products in the United States.  Pursuant to the Commercialization Agreement, Licensee assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing. The Company also agreed to provide services to Licensee, including to arrange for the supply of NUCYNTA products by the Company’s existing contract manufacturing organizations (“CMOs”) (the “Facilitation Services”).
License Property
NUCYNTA ER (Tapentadol Extended Release Tablets) and NUCYNTA IR (NUCYNTA) (Tapentadol) is an extended release version of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and for which alternate treatment options are inadequate. NUCYNTA is an immediate release version of tapentadol that is indicated for the management of moderate to severe acute pain in adults.
Field of Use
This Agreement pertains to the drug industry relating to pain management.

IPSCIO Record ID: 2939

License Grant
An exclusive License Agreement that grants the Licensee an exclusive License to develop and commercialize Opana® and Opana® ER in Canada, Australia and New Zealand.  Regulatory approval must be received prior to any sale of the Licensed products.
License Property
Opana is in a group of drugs called narcotic pain relievers. It is similar to morphine.  Opana is used to treat moderate to severe pain.  Opana ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.
Field of Use
The rights granted apply to the healthcare industry relating to the drug market.

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 233488

License Grant
The Licensor and Chinese Licensee entered into an exclusive licensing agreement for the development and commercialization of Oliceridine in United States and China.
License Property
Oliceridine is a G protein biased ligand of the µ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred.
Field of Use
Oliceridine is an opioid drug that is under evaluation in human clinical trials for the intravenous treatment of severe acute pain.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.